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Background.Anemia associated with deﬁciencies in iron, folic acid, and vitamin B12 are very common after Laparoscopic Roux-
en-Y Gastric Bypass (LRYGB) surgery for morbid obesity. This study was conducted to evaluate the prevalence of anemia after
LRYGB. Patients and Methods. A total of 377 morbid obese patients were included in our study. All patients underwent a LRYGB.
Hematologicparameterswereobtainedpriortoandaftersurgeryonstandardizedtimeintervals. Results.Anemiawaspresentin21
(P = 0.02) patients after surgery. Iron, folic acid, and vitamin B12 deﬁciencies were diagnosed in 66%, 15%, and 50% of patients,
respectively. In 86% of patients, anemia was accompanied by one of these deﬁciencies. Conclusion. These results show that anemia
and deﬁciencies for iron, folic acid deﬁciency, and vitamin B12 are very common within the ﬁrst year after LRYGB. We advise a
minimaldailyintakeof65mgofironinmaleand100mginfemalepatients,350µgofvitaminB12,and400µgoffolicacid.Patients
undergoing LRYGB must be closely monitored for deﬁciencies pre- a n dp o s t o p e r a t i v ea n ds u p p l e m e n t e dw h e nd e ﬁ c i e n c i e so c c u r .
1.Introduction
Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) is one
of the most commonly performed bariatric procedures to
establish weight loss in morbid obese patients. A sustained
Excess Weight Loss (EWL) of 50–70% is obtained in at least
50% of the patients by combining restrictive and malabsorp-
tion techniques. Sustained weight loss is associated with a
decrease in obesity-related morbidity and mortality and an
increase in quality of life [1–5].
However, due to malabsorption and insuﬃcient intake,
LRYGB patients are prone to develop deﬁciencies in many
macro- and micronutrients. Most common are deﬁciencies
in iron, folate, and vitamin B12, all of which can lead to
anemia. Once these deﬁciencies are present, they can be
diﬃcult to treat by oral vitamin and mineral supplements.
Therefore, patients who undergo RYGB should be evaluated
priortosurgeryfordeﬁcienciesandtreatedaccordingly.After
surgery, supplementation and close monitoring is warranted
[1, 2, 6–8].
A number of possible risk factors for developing anemia
have been previously researched. Diﬀerences in sex as well
as length of Roux-en-Y limb are described as contributing
factors for the development of certain deﬁciencies [3].
Also we researched whether the amount of weight loss or
an Adjustable Gastric Band (AGB) prior to the LRYGB
inﬂuenced the amount of deﬁciencies.
AlthoughweightlosseﬀectsofRYGBarewellestablished,
the number of studies addressing nutrient deﬁciencies and
anemia is limited. Furthermore, the studies conducted so
far often include only a small number of patients and are
incongruent in their ﬁndings [1, 7]. For this reason we
conducted a prospective study to investigate the prevalence
of anemia and deﬁciencies in iron, folate, and vitamin B12 in
the ﬁrst year after LRYGB in our patients.
2. Patients andMethods
Between January 2005 and October 2009 a total of 416
patients underwent an LRYGB in our hospital. All patients
werescreenedbyamultidisciplinaryteampreoperativelyand
met the criteria stated by the NIH Consensus Development
Conference Panel for bariatric surgery [9]. Patients who
were unable to attend our standardized follow-up protocol2 Journal of Obesity
Table 1: Demographics.
Parameter Values (standard deviation)
Number of patients 377
Male 102 (27.1%)
Female 275 (72.9%)
Age 43.4 (18–63)
Age male 46.0 (20–63)
Age female 42.5 (18–62)
Initial weight in kg 137.5 (±22.6)
Male 151.4 (±22.1)
Female 132.4 (±20.6)
Initial BMI in kg/m2 46.8 (±6.3)
Male 47.0 (±6.4)
Female 46.7 (±6.2)
were excluded. Also excluded were patients with laboratory
evaluations that surpassed the six-and 12-month evaluation
with two and three months respectively. Research nurses
assured a minimum of data loss. Hence being part of our
standard intake protocol, all patients were informed about
this study. A total number of 377 (91%) patients scheduled
for LRYGB were included in this study. We included 102
(27%) male patients and 275 (73%) female patients with a
mean age of 43 (18–63) years. Medium follow-up time was
13.7 months. Demographics are shown in Table 1.
In our clinic, the proximal gastric volume is reduced by
stapling of a 30cc proximal gastric pouch and connecting a
100or150cmroux-en-ylimbasanenteroenterostomytothe
jejunum 40cm from the ligament of Treitz. Limb length was
based on the patients BMI between 2005 and 2007. Patients
with a BMI > 40kg/m2 received a 100cm limb. Patients with
aB M I> 50kg/m2 or a failing gastric band were treated with
a 150cm limb. Since 2007, all patients received a 150cm
limb. After surgery, patients were followed up at 1, 3, 6, and
12 months. Standard laboratory evaluation was performed
preoperatively consisting of a complete blood count, a mean
cell volume (MCV), and kidney function. After six and
twelve months, laboratory evaluation was repeated along
with plasma levels for iron, total iron binding capacity
(TIBC), serum folate levels, and serum vitamin B12 levels.
Patients were instructed to take a standard multivitamin
tablet three times daily. These tablets contained at least 7mg
of iron, 100µg of folic acid, and 0.5µg of vitamin B12 per
tablet. Our standard postoperative medication consisted of a
CaD 1000/880 sachet to prevent bone loss, Omeprazol 40mg
once daily to prevent ulceration of the staple line and the
remaining stomach, and 5700U of Fraxiparine once daily for
six weeks postoperative for preventing thrombosis. During
each visit patients were asked about their medication use so
as to estimate their compliance to our described medication.
Anemia was deﬁned as a hemoglobin (Hb) level
<8.4mmol/L in men and <7.4mmol/L in women. MCV
was deﬁned normal between 80 and 100fL. Iron deﬁciency
was deﬁned by serum levels <9.0µmol/L. Total iron binding
capacity was deﬁned as high when >80%. Folate deﬁciency
Table 2: Laboratory outcomes before RYGB.
Level Number of patients (%)
Hb Low 27 (7,9%) of which 9 microcytic
Normal 350 (92,9%) of which 13 microcytic
and 5 macrocytic
MCV
Microcytic 22 (5,8%)
Normocytic 350 (92,9%)
Macrocytic 5 (1,3%)
was deﬁned by serum levels <9.0nmol/L. Cobalamin deﬁ-
ciency was deﬁned by serum levels <150pmol/L. Once a
deﬁciency was identiﬁed treatment was started accordingly.
3. Statistics
Data were prospectively collected and evaluated using
SPSS16 for Windows. All data are reported as mean ±
standard error of the mean. To evaluate the results between
groups,logisticregressionwasused.Evaluationoflaboratory
results was performed using a paired T-tests. P<0.05 was
considered signiﬁcant.
Patients who were anemic preoperative were excluded
for the 12 months evaluation (Table 3 N = 350) and were
evaluated separately (Table 4 N = 27).
4. Results
Beforesurgery,anemiawaspresentin27(7%)patients. After
twelve months, 66 (19%) patients had developed anemia de
novo, of which 19 (29%) were microcytic. In these patients
mean Hb levels dropped from 8.2mmol/L to 7.1mmol/L
(P<0.001). Total prevalence of anemia diagnosed in
the ﬁrst year, including preoperative anemic patients, was
25%. Preoperative laboratory results are shown in Table 2.
A total of 93 patients were diagnosed with or developed
anemia during the ﬁrst postoperative year. The percentage
of deﬁciencies in patients with anemia are separately shown
in Table 3. The percentage of patients with iron, folic acid,
and vitamin B12 deﬁciencies were 66%, 15%, and 50%,
respectively. In 86% of patients, anemia was accompanied by
one of these deﬁciencies.
Analysis of deﬁciencies in all patients is shown in Table 4.
Iron deﬁciency after one year was identiﬁed in 33% of
patients and in 61% of our patients with anemia de novo
(P<0.001). The percentage of patients with folic acid
and vitamin B12 deﬁciency were 14% and 40%, respectively.
Three patients developed macrocytic red blood cells, and
in two cases a vitamin B12 deﬁciency was found. Of all
patients, 239 (63%) were diagnosed with at least one of the
deﬁciencies mentioned above.
Risk factor analysis is presented in Table 5.M a n yd i ﬀer-
ences between male and female patients were found in the
prevalence of iron (38% versus 17%, P = 0.02), and vitamin
B12 (42% versus 21% P = 0.03) deﬁciencies. However,
the percentage for developing anemia in these groups was
similar, 20%. Male patients had a 45% risk of being
diagnosed with an iron, folic acid, or vitamin B12 deﬁciency,
whereas female patients had a 68% risk (P = 0.004).Journal of Obesity 3
Table 3: 12 Month evaluation of anemic patients.
Anemia preoperative (%) Anemia de novo (%) Anemia total (%)
N patients 27 (7.1%) 66 (18.8%) 93 (24.7%)
MCV Micro 10 (37.0%) 19 (18.8%) 29 (31.2%)
Macro 0 (0%) 1 (1.5%) 1 (1.0%)
High TIBC 4 (14.8%) 10 (15.2%) 14 (15.1%)
Iron deﬁciency 21 (77.8%) 40 (60.6%) 61 (65.6%)
Folic acid deﬁciency 4 (14.8%) 11 (16.7%) 15 (16.1%)
Vitamin B12 deﬁciency 14 (52%) 33 (50.0%) 47 (50.4%)
Total deﬁciency 23 (85.2%) 57 (86.4%) 80 (86.0%)
In the anemia preoperative column, laboratory results are shown of patients with anemia preoperative. In the anemia de novo column, patients with anemia
preoperative were excluded. In the anemia total column, all patients are evaluated.
Table 4: 12 Month evaluation of all RYGB patients.
Month
6( % )
Month
12 (%)
Total
(%)
Anemia 50
(13.3%)
71
(18.8%)
93
(24,7%)
MCV Micro 24
(6.4%)
20
(5.3%)
34
(9.0%)
Macro 4
(1.1%)
6
(1.6%)
8
(2.1%)
Elevated TYBC 17
(4.5%)
26
(6.9%)
32
(8.5%)
Iron deﬁciency 79
(21%)
78
(20.7%)
124
(32.9%)
Folic acid deﬁciency 34
(9.0%)
25
(6.6%)
51
(13.6%)
Vitamin B12 deﬁciency 89
(23.6%)
71
(18.8%)
152
(40.2%)
Total deﬁciency 175
(46.4%)
150
(39.8%)
239
(63.4%)
T6 = laboratory ﬁndings (%) at 6 months, T12 = laboratory ﬁndings (%) at
12 months. N = 377.
Further analysis was done to investigate the role of Roux-
en-Y limb length in the onset of deﬁciencies. No signiﬁcant
diﬀerences were found. A number of patients were treated
with a AGB prior to RYGB surgery. A signiﬁcant diﬀerence
(24% versus 39% P = 0.03) in vitamin B12 deﬁciencies
between these groups was found. Surprisingly the percent-
ages for anemia, folic acid, and vitamin B12 deﬁciencies were
lower in the group who had a previous AGB placement.
Patients who lost over 70% of their excess weight in one
year were less likely to develop anemia and deﬁciencies for
folic acid and vitamin B12 compared to patients below 70%
EWL.
5. Discussion
Bypassing the duodenum and proximal jejunum leads to
a decrease in absorption surface for speciﬁc nutrients and
causesareductionintheabsorptivecapacity.AfteranLRYGB
the most common reported are iron and vitamin B12 deﬁ-
ciencies. Deﬁciencies in these micronutrients are well known
causes for anemia [1, 7, 10]. Published reports on metabolic
deﬁciencies after RYGB with diﬀerent follow-up periods
found anemia varying from 18 to 35%. Iron deﬁciency was
reported in 20–49% in these studies. Folate deﬁciency was
found in 0–18% of the cases. Vitamin B12 deﬁciency varied
from 26 to 70% [11–16]. Although a relative short followup
of only one year, we found high percentages in folic acid and
vitamin B12 deﬁciencies, of 19 and 36%, respectively.
Iron deﬁciency after RYGB is due to a combination
of factors and is the main cause for developing anemia
after an RYGB [17, 18]. Absorption is dependent on the
pH of the stomach. Acid reduces iron from a ferric state
(Fe3+) to a ferrous state (Fe2+), which is readily absorbed
in the duodenum and proximal jejunum. Due to the RYGB
conﬁguration, iron passes through the small gastric pouch
without being reduced to the ferrous state. This eﬀect is
further enhanced by the prescribed protonpump inhibitors
and calcium. After ingestion, iron bypasses the absorptive
surface of the duodenum and jejunum. Iron intake is further
reduced by the frequently found intolerance for red meat
[10, 19]. A normal individual requires 1-2mg of iron daily
as a minimum. Especially premenopausal female are prone
for developing iron deﬁciency [3, 11, 12, 17].
Preoperative8%ofourpatientswereanemicandanother
5% had micro- or macrocytic red blood cells. These ﬁndings
are most likely due to an unvaried intake of macro- and
micronutrients by these patient [10, 19]. This shows that
testing patients for anemia and deﬁciencies in iron, folate,
and vitamin B12 preoperative is needed to achieve the best
medical care for the bariatric patient. Patients should be
treated for their deﬁciencies preoperative to prevent symp-
tomatic anemia, deﬁciencies, and possible complications
during and after surgery. In case of preoperative deﬁciencies,
patients in our clinic are treated with high doses of iron
(200mg a day), vitamin B12 injections (3000µge v e ryw e e k ) ,
and folic acid (2mg a day). These amounts are used until an
adequate serum level is reached.
In our study, 56% of the patients who developed anemia
d en o v oa l s oh a da ni r o nd e ﬁ c i e n c ya n d4 2 %h a dm i c r o c y t i c
red blood cells. Of the patients who did not develop anemia
within the ﬁrst year, another 32% appeared to be iron
deﬁcient and may develop anemia in the near future if not
treated. In our study, we prescribed all patients Omeprazol4 Journal of Obesity
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tablets and CaD 1000/880 sachets. This may increase the
percentage of iron deﬁciencies because Omeprazol reduces
acid secretion and subsequent iron absorption. Calcium can,
when taken around the same time as iron, decrease the
uptake of iron up to 60% [20]. The amount of iron (21mg
daily) supplemented did not prevent iron deﬁciency in a
large number of patients. Most recent recommendations
in the literature advise a daily intake of 40 to 65mg of
elemental iron per day for male and 100mg per day for
female patients. Vitamin C added to this regimen may also
improve absorption [15, 18, 19].
Folic acid is present in food as polyglutamates and must
be hydrolyzed to monoglutamates by the intestinal brush
border. Folic acid absorption predominantly takes place in
the upper third of the small intestine but can be absorbed
throughout the small intestine [18]. Absorption is pH
dependent and therefore partially facilitated by hydrochloric
acid. Additionally, vitamin B12 acts as a coenzyme in
converting folic acid to an absorbable form thus a vitamin
B12 deﬁciency may result in a folate deﬁciency [20, 21].
Due to the low acid production of the proximal pouch
and the bypassing of the upper third of the small intestine,
RYGB patients are at risk for developing folic acid deﬁciency
[21,22].Enterohepaticrecirculationisanimportantfactorin
preservingthebodypooloffolate[19].Anothercontributing
factor for developing a folic acid deﬁciency may be due to
the malabsorption and the short bowel in RYGB patients.
Despite these apparent mechanisms for folate deﬁciency,
decreased dietary intake of folic acid seems the dominant
cause. Since folic acid reserves are low with an average of
10mg, a daily requirement of 50µg, and a deﬁcit absorption,
deﬁciency can occur rapidly [20, 23].
In this study, 19% of the patients were diagnosed
with folic acid deﬁciency. A number of studies found a
substantial decrease in folic acid deﬁciencies over the years.
An explanation for this decrease may be that folic acid
absorption in the distal small intestine compensates for the
reduced absorption capacity. Another mechanism might be
based on bacteria in the upper small bowel who produce
more folic acid over time [24, 25].
The 300µg of folic acid prescribed per day appears
insuﬃcient to avoid a deﬁciency in the ﬁrst year. A suﬃcient
quantity of folic acid should be at least 400µg per day, while
most authors prescribe 1mg of folic acid a day [12, 20]. Folic
acid deﬁciency may be of great concern in female patients
who want to became pregnant in the near future after RYGB.
Although uncommon, reports of neural tube defects have
beenreportedininfantsafterRYGBsurgery[12,26].Woman
of reproductive age should be monitored closely, bearing in
mind that one of the reasons for undergoing an RYGB is
decreased fertility due to morbid obesity.
Vitamin B12 in food is bound to proteins and ﬁrst needs
to be released by pepsin and hydrochloric acid before it
can be bound by intrinsic factor (IF). When the released
vitamin B12 in a normal individual enters the duodenum, it
is bound to IF released from the parietal cells of the stomach
facilitatedbypepsinandpancreaticenzymes.Inthisstate,the
bound vitamin B12 is eventually absorbed in the terminal
ileum. After RYGB, vitamin B12 cannot be released from
the food and is hardly bound to IF due to the bypassing of
the stomach and duodenum and the reduced amount of IF
released [27, 28]. The frequently found intolerance for red
meat and milk might also play a role, as these products are
rich in vitamin B12. In healthy subjects, a daily minimal dose
of 2µg vitamin B12 per day is needed. A normal individual
has a vitamin B12 reserve of 2000µg, which should last for a
minimum of two years [19, 24, 29, 30].
LRYGB patients appear to have much lower vitamin
B12 reserves than healthy individuals, probably due to
inadequate dietary intake preoperatively. The multivitamins
prescribed contains 1,5µg of vitamin B12 per day. Several
studies have shown that a 300–500µg dose of vitamin B12
is suﬃcient. Others recommend sublingual administration
or intramuscular injections of 1000–3000µge v e r ym o n t ht o
every six months and report similar outcomes for resulting
vitamin B12 levels [12, 15, 28, 31–33]. In the case of vitamin
B12, the prescribed Omeprazol may also decrease absorption
[20].Althoughnoneofourpatientsbecamesymptomaticfor
B12deﬁciency,therehavebeenreportsofpatientsdeveloping
Wernicke’s encephalopathy and megaloblastic anemia years
after RYGB [34–39].
The risk factors studied for developing metabolic deﬁ-
ciencies showed a number of interesting results. A number of
studies reported a diﬀerence for developing anemia and iron
deﬁciencybetweenmaleandfemalepatientswhohadunder-
went RYGB [11, 12, 17]. Anemia and iron deﬁciency are
thoughttobehigheramongwoman,becausepremenopausal
women lose iron during menstruation every month and
often have no iron reserves [11, 12, 17, 40]. This study did
not ﬁnd a signiﬁcant diﬀerence in the prevalence for anemia
between the sexes. In fact, the prevalence was identical at
20%. This shows that the ﬁrst year after LRYGB the risk for
developinganemiaisequalbetweenmaleandfemalepatients
after RYGB surgery for morbid obesity. We did, however,
ﬁnd signiﬁcant higher percentages for iron and vitamin B12
deﬁciencies in female patients. From these data one could
conclude that on the long run female patients may have a
higher risk for developing anemia. The diﬀerence in iron
deﬁciencies between males and females can be explained by
theaveragelowerironreservesoffemales,combinedwiththe
loss of iron during menstruation. The diﬀerence in vitamin
B12 might be explained by the average lower daily intake of
vitamin B12 by female patients compared to male patients
(4µgv e r s u s7µg). Of all the patients who developed anemia,
71% were female. This greater number is due to the fact that
a greater number of patients undergoing RYGB were female.
ThediﬀerentlengthsoftheRoux-en-Ylimbdidnotshow
any signiﬁcant outcomes. Although the 150cm limb group
showed a 6% higher prevalence for anemia and lower values
for folic acid and vitamin B12 deﬁciencies, these values were
not signiﬁcant. Brolin et al. also found lower deﬁciency rates
for vitamin B12 with an increase of the Roux-en-Y limb
length.
Patients with an AGB prior to an RYGB had a lower
prevalence’s for anemia, folic acid deﬁciency, and even a
signiﬁcant lower risk of vitamin B12 deﬁciency (P = 0.03).
These patients were already used to taking multivitamin
tablets during the period they had an AGB. Thus resulting6 Journal of Obesity
in higher baseline values and a better compliance (92
versus 76%). These diﬀerences may explain the unexpected
diﬀerences in deﬁciencies found.
We expected the group who lost >70% of their EWL to
have higher prevalence’s of deﬁciencies due to a decreased
intake of macro- and micronutrients. The prevalence of iron
deﬁciency was as expected higher in the >70% group, but all
the other prevalence’s were lower in this group. The diﬀer-
ence in vitamin B12 deﬁciency was almost signiﬁcant (P =
0.07) and might be explained by the release of vitamin B12
fromtheshrinkingliverandfattytissue.Thismechanismwill
onlyprotectthesepatients during therapid weightloss. After
this period, the micronutrient stores will be depleted.
6. Conclusion
Our results show that anemia and deﬁciencies for iron, folic
acid, and vitamin B12 are very common the ﬁrst year after
LRYGB. Women are at risk for developing iron deﬁciency
and vitamin B12 deﬁciency and have a greater overall risk for
developing one of the deﬁciencies researched. Our standard
policy for supplementation of multivitamin tablets after
LRYGB failed to prevent deﬁciencies. We advise a minimal
daily intake of 65mg of iron in male and 100mg in female
patients, 350µg of Vitamin B12 and 400µg of folic acid.
With this paper we want to create awareness for screening
RYGB patients for deﬁciencies and correcting these within
the ﬁrst year. Furthermore, supplementing these patients
with multivitamins should only be regarded as a base upon
which a patient-speciﬁc regimen for micronutrients should
be built.
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